Regulatory and Washington

In its 2016 report on generics savings for the Generic Pharmaceutical Assocation, Quintiles IMS included a snapshot on one of the quickly burgeoning fields of more affordable medicine, biosimilars. Currently, biosimilars are expected to save the healthcare system between $44 billion and $250 billion in the next 10 years.

(To view the full Category Review, click here.)

Generic medications saved the U.S. healthcare system more money in 2015 than ever before, according to the eighth-annual “2016 Generic Drug Savings & Access in the United States Report,” compiled by Quintiles IMS Institute on behalf of the Generic Pharmaceutical Association.

(To view the full Category Review, click here.)

According to QuintilesIMS National Prescription Audit data from August, Aurobindo Pharma USA continues to eclipse market growth predictions, most recently moving into the Top 6 among all generic companies in prescriptions dispensed.

(To view the full Category Review, click here.)

More and more, meter manufacturers today are differentiating their offerings not by the traditional micrometers of blood necessary for a viable glucose reading or the value inherent in the cost of test strips, but in the accompanying adherence app or other technologies that will help diabetes patients better navigate their disease states.

(To view the full Diabetes Report, click here.)

In the nearly five years since the Generic Drug User Fee Agreement was enacted under the Food and Drug Administration Safety and Innovation Act of 2012, through the FDA’s Office of Generic Drug, GDUFA has generated some $1.5 billion in user fees and has seen 1,992 approvals issued.

(To view the full Category Review, click here.)

ARLINGTON, Va. – The Center for Disease Control and Prevention Foundation's Judy Monroe, president and CEO, will accept the 2016 NACDS Foundation Excellence in Patient Care Award at the NACDS Foundation Dinner on Dec. 1, 2016, in New York, the Foundation announced Monday.

ARLINGTON, Va. — The Healthcare Distribution Alliance  on Thursday presented two viable scenarios out of its Pilot Study for Saleable Returns, a study designed to help pharmaceutical manufacturers and distributors comply with requirements set forth by the Drug Supply Chain Security Act.